Suppr超能文献

家族性血栓形成倾向:遗传风险因素与管理

Familial thrombophilia: genetic risk factors and management.

作者信息

Makris M, Rosendaal F R, Preston F E

机构信息

Department of Haematology, University of Sheffield, Royal Hallamshire Hospital, UK.

出版信息

J Intern Med Suppl. 1997;740:9-15.

PMID:9350176
Abstract

There are now a number of potential candidates for inherited thrombophilia but a definite causal relationship has been established for only a proportion of these. Accepted causes of familial thrombophilia include the factor V Leiden defect and the prothrombin 20210 G > A variant, as well as deficiencies of antithrombin, protein C and protein S. Together these inherited abnormalities account for 30-50% of individuals presenting with venous thromboembolism. Factor V Leiden, which is present in up to 7% of the European population, is the most common cause of familial thrombophilia. On a worldwide basis its prevalence varies greatly with ethnic origin. In common with other types of familial thrombophilia the frequency of factor V Leiden is highly dependent on the population group studied. Venous thromboembolism, present in approximately 55% of individuals with familial coagulation inhibitor deficiencies, is the predominant clinical manifestation of familial thrombophilia. There are indications that the venous thrombotic risk is somewhat less in those with factor V Leiden. The thrombotic risk is markedly increased in those with combined defects and in those who are homozygous for factor V Leiden. Risk factors for thrombosis include pregnancy, including the puerperium, surgery, oral contraceptive usage and prolonged periods of immobilization. A substantial proportion of venous thrombotic events may occur spontaneously, i.e. without an obvious precipitating event. The management of patients with familial thrombophilia comprises counselling, thromboprophylaxis and thrombosis treatment. Although the immediate treatment of an acute thrombotic event is not significantly different from that of patients without recognised abnormalities, detailed patient management is seriously hampered by a lack of appropriate clinical trials. Prospective clinical studies, designed to ascertain individual thrombotic risk and to evaluate different therapeutic strategies are urgently required.

摘要

目前有许多潜在的遗传性血栓形成倾向候选因素,但仅其中一部分已确定存在明确的因果关系。公认的家族性血栓形成倾向病因包括因子V莱顿缺陷、凝血酶原20210 G>A变异,以及抗凝血酶、蛋白C和蛋白S缺乏。这些遗传性异常共同导致30%-50%的静脉血栓栓塞患者发病。因子V莱顿在欧洲人群中高达7%,是家族性血栓形成倾向最常见的病因。在全球范围内,其患病率因种族不同而有很大差异。与其他类型的家族性血栓形成倾向一样,因子V莱顿的发生率高度依赖于所研究的人群组。静脉血栓栓塞在大约55%的家族性凝血抑制剂缺乏患者中出现,是家族性血栓形成倾向的主要临床表现。有迹象表明因子V莱顿患者的静脉血栓形成风险略低。合并缺陷的患者以及因子V莱顿纯合子患者的血栓形成风险显著增加。血栓形成的危险因素包括妊娠(包括产褥期)、手术、口服避孕药使用和长期制动。相当一部分静脉血栓事件可能是自发发生的,即没有明显的诱发事件。家族性血栓形成倾向患者的管理包括咨询、血栓预防和血栓治疗。尽管急性血栓事件的即时治疗与无明显异常的患者没有显著差异,但由于缺乏适当的临床试验,详细的患者管理受到严重阻碍。迫切需要开展前瞻性临床研究,以确定个体血栓形成风险并评估不同的治疗策略。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验